{"id":3626,"date":"2022-09-01T16:30:52","date_gmt":"2022-09-01T08:30:52","guid":{"rendered":"http:\/\/www.sinotau.com\/homepage\/"},"modified":"2025-05-29T10:47:26","modified_gmt":"2025-05-29T02:47:26","slug":"homepage","status":"publish","type":"page","link":"https:\/\/www.sinotau.com\/en\/","title":{"rendered":"Home page"},"content":{"rendered":"\n<section class=\"page page-home-s1\"><video class=\"vid\" src=\"\/wp-content\/uploads\/2024\/05\/\u5148\u901a\u9996\u9875\u89c6\u9891.mp4\" poster=\"\/wp-content\/themes\/qnz\/assets\/img\/banners\/slider01.jpg\" autoplay=\"\" muted=\"\" loop=\"\" webkit-playsinline=\"true\" playsinline=\"true\" x-webkit-airplay=\"allow\" x5-video-player-type=\"h5\" x5-video-player-fullscreen=\"true\" x5-video-orientation=\"portraint\"><\/video><div class=\"txt-container\">\n        <div class=\"container\">    \n          <div class=\"text20\">                        <\/div>\n          <h2 class=\"text60\">Invent radiopharmaceuticals for lives <\/h2>\n          <div class=\"text32 mb-media-3\">Lays out  <strong>oncology , neurology and cardiology<\/strong> <\/div>\n          <div class=\"go\"> <a href=\"https:\/\/www.sinotau.com\/en\/products\/\">Products<i class=\"iconfont icon-right\"><\/i><\/a><\/div>\n        <\/div>\n      <\/div>\n    <\/section>\n\n\n<section class=\"page page-home-s2\">\n<div class=\"row g-0 align-items-center\">\n<div class=\"col-md-6\">\n<div class=\"left_col wow fadeInUp\">\n<div class=\"sub_title\">Who We Are?<\/div>\n<h2 class=\"title text32 mb-media-3\">A company ahead of the innovative radiopharmaceuticals in China.<\/h2>\n<p class=\"des mb-media-3\">Since 2014, Sinotau started the R&amp;D of next-generation radiopharmaceuticals,which is an innovative pharmaceutical company specializing in the R&amp;D, production, clinical application and marketing of radiopharmaceuticals<\/p>\n<div class=\"more\"><a class=\"btn btn-primary btn-radius\" href=\"https:\/\/www.sinotau.com\/en\/about\/\">About Sinotau<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"col-md-6\">\n<div class=\"right_col wow fadeInUp pt-media-5 pb-media-5\">\n<div class=\"data\">\n<div class=\"row\">\n<div class=\"col-6\">\n<div class=\"item\">\n<div class=\"num\">\n<div class=\"counter\">9<\/div>\n<p>Year+<\/p>\n<\/div>\n<div class=\"des\">Years of radiopharmaceutical R&amp;D<\/div>\n<\/div>\n<\/div>\n<div class=\"col-6\">\n<div class=\"item\">\n<div class=\"num\">\n<div class=\"counter\">100<\/div>\n<p>%<\/p>\n<\/div>\n<div class=\"des\">Focus on radiopharmaceuticals<\/div>\n<\/div>\n<\/div>\n<div class=\"col-6\">\n<div class=\"item\">\n<div class=\"num\">\n<div class=\"counter\">1<\/div>\n<p>\u00a0<\/p>\n<\/div>\n<div class=\"des\">Radiopharmaceutical Product<\/div>\n<\/div>\n<\/div>\n<div class=\"col-6\">\n<div class=\"item\">\n<div class=\"num\">\n<div class=\"counter\">10<\/div>\n<p>+<\/p>\n<\/div>\n<div class=\"des\">Pipeline<\/div>\n<\/div>\n<\/div>\n<div class=\"col-6\">\n<div class=\"item\">\n<div class=\"num\">\n<div class=\"counter\">5<\/div>\n<p>+<\/p>\n<\/div>\n<div class=\"des\">R&amp;D and production sites<\/div>\n<\/div>\n<\/div>\n<div class=\"col-6\">\n<div class=\"item\">\n<div class=\"num\">\n<div class=\"counter\">400<\/div>\n<p>+<\/p>\n<\/div>\n<div class=\"des\">Skilled employees<\/div>\n<\/div>\n<\/div>\n<div class=\"col-6\">\n<div class=\"item\">\n<div class=\"num\">\n<div class=\"counter\">80<\/div>\n<p>+<\/p>\n<\/div>\n<div class=\"des\">Authorized Patent<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<section class=\"page page-home-s3\">\n<div class=\"row g-0 align-items-lg-center\">\n<div class=\"col-md\">\n<div class=\"bg\">\n<div class=\"pic\"><img decoding=\"async\" src=\"\/wp-content\/themes\/qnz\/assets\/img\/nb_02.jpg\" alt=\"Radiopharmaceutical Structure\" \/>\n<div class=\"dot\" style=\"z-index: 300;\">\n<div class=\"clice wow fadeInUp\">\u00a0<\/div>\n<div class=\"tip\">\n<h4>Chelate<\/h4>\n<\/div>\n<\/div>\n<div class=\"dot\" style=\"left: 75%; top: 64%;\">\n<div class=\"clice wow fadeInUp\">\u00a0<\/div>\n<div class=\"tip\">\n<h4>Linker<\/h4>\n<\/div>\n<\/div>\n<div class=\"dot\" style=\"left: 85%; top: 65%;\">\n<div class=\"clice wow fadeInUp\">\u00a0<\/div>\n<div class=\"tip\">\n<h4>Radioisotopes<\/h4>\n<\/div>\n<\/div>\n<div class=\"dot\" style=\"left: 36.5%; top: 85%;\">\n<div class=\"clice wow fadeInUp\">\u00a0<\/div>\n<div class=\"tip\">\n<h4>Targeting Molecule<\/h4>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"col-md\">\n<div class=\"right_col wow fadeInUp\">\n<div class=\"sub_title\">Innovation<\/div>\n<h2 class=\"title text32\">From precise diagnostics to targeted therapies, we pioneer next-generation solutions helping improve therapeutic outcomes and the lives of patients.<\/h2>\n<p class=\"des\">Sinotau has established differentiated and highly competitive pipeline out of high attention of the R&amp;D innovation and for the sustainable development and theranostic radiopharmaceuticals with the characteristic and diverse innovation ability of our own team.<\/p>\n<div class=\"more\"><a class=\"btn btn-primary btn-radius\" href=\"https:\/\/www.sinotau.com\/en\/innovating\/\">Pipeline<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8f761849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column page page-home-s4 is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"news-header\">\n<div class=\"row align-items-center mb-media-2\">\n<div class=\"col-md\">\n<div class=\"title-section wow fadeInUp\">\n<h4 class=\"sub_title\">News<\/h4>\n<h3 class=\"title text32\">Sinotau is totally engrossed in research and development of radiopharmaceuticals. Learn about our latest progress.<\/h3>\n<\/div>\n<\/div>\n<div class=\"col-md-auto\">\n<div class=\"more\"><a class=\"btn btn-primary btn-radius\" href=\"https:\/\/www.sinotau.com\/en\/category\/company-news\/\">Read More<\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n<div class=\"news-list\"><div class=\"swiper newsSliders\"><div class=\"swiper-wrapper\"><div class=\"swiper-slide\"><a class=\"item wow fadeInUp\" href=\"https:\/\/www.sinotau.com\/en\/2026\/06\/novel-alpha-radioligand-therapy-xtr022-clinical-data-presented-at-asco-2026\/\"><h3 class=\"title\">Novel Alpha Radioligand Therapy XTR022 Clinical Data Presented at ASCO 2026<\/h3><p class=\"des\">Sinotau today announced that clinical data for XTR022 ([\u00b2\u00b2\u2075Ac]Ac-XT381), its novel alpha-particle radioligand therapy, were presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The study evaluated the safety, tolerability and preliminary efficacy of XTR022 in patients with previously treated, PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Study Design [&hellip;]<\/p><div class=\"date\">2026-06-01<\/div><\/a><\/div><div class=\"swiper-slide\"><a class=\"item wow fadeInUp\" href=\"https:\/\/www.sinotau.com\/en\/2026\/04\/sinotau-to-present-clinical-research-results-of-alpha-nuclide-therapy-project-at-asco\/\"><h3 class=\"title\">Sinotau to Present Clinical Research Results of Alpha Nuclide Therapy Project at ASCO<\/h3><p class=\"des\">As the most important event in the global oncology field, the 2026 American Society of Clinical Oncology(ASCO) Anual Meeting will be held in Chicago from May 29 to June 2. Sinotau will present clinical research results of its independently developed novel alpha-particle radioligand therapy [225Ac]Ac-PSMA-XT for the treatment of metastatic castration-resistant prostate cancer (mCRPC) at [&hellip;]<\/p><div class=\"date\">2026-04-23<\/div><\/a><\/div><div class=\"swiper-slide\"><a class=\"item wow fadeInUp\" href=\"https:\/\/www.sinotau.com\/en\/2026\/04\/nmpa-accepted-ind-application-for-xtr021-an-innovative-radiopharmaceutical\/\"><h3 class=\"title\">NMPA Accepted IND Application for XTR021, an Innovative Radiopharmaceutical<\/h3><p class=\"des\">Sinotau is pleased to announce that the Investigational New Drug (IND) application for XTR021, a Class 1 innovative radiopharmaceutical developed in-house, has been accepted by the National Medical Products Administration (NMPA). XTR021 is a 177Lu-labeled, PSMA-targeted radioligand for the treatment of prostate cancer. Preclinical studies demonstrate that, owing to its novel molecular design, XTR021 exhibits [&hellip;]<\/p><div class=\"date\">2026-04-16<\/div><\/a><\/div><div class=\"swiper-slide\"><a class=\"item wow fadeInUp\" href=\"https:\/\/www.sinotau.com\/en\/2025\/10\/top-oncology-journal-esmo-lba-concurrent-release-xtr008-receives-international-top-level-dual-endorsement\/\"><h3 class=\"title\">Top Oncology Journal &amp; ESMO LBA Concurrent Release: XTR008 Receives International Top-Level Dual Endorsement<\/h3><p class=\"des\">Sinotau is pleased to announce that the results of the Phase III clinical trial in China for our self-developed radionuclide therapeutic drug, \u00b9\u2077\u2077Lu-Dotatate(XTR008), have been officially published in the prestigious international oncology journal&nbsp;Annals of Oncology&nbsp;(Impact Factor: 65.4). Concurrently, the latest analysis results from this study were successfully selected as a Late-Breaking Abstract (LBA) for this [&hellip;]<\/p><div class=\"date\">2025-10-20<\/div><\/a><\/div><div class=\"swiper-slide\"><a class=\"item wow fadeInUp\" href=\"https:\/\/www.sinotau.com\/en\/2025\/10\/sinotau-selected-as-inaugural-member-unit-of-national-cardiovascular-imaging-committee\/\"><h3 class=\"title\">Sinotau\u00a0Selected as Inaugural Member Unit of National Cardiovascular Imaging Committee<\/h3><p class=\"des\">Recently, the Cardiovascular Imaging Professional Committee of the National Expert Committee on Cardiovascular Diseases&nbsp;was officially established. Initiated by experts including Academician Hu Shengshou and with Academician Wang Zhenchang serving as its first Chairman, the committee brings together hundreds of top experts in the field of cardiovascular imaging in China. Its establishment marks a new stage [&hellip;]<\/p><div class=\"date\">2025-10-10<\/div><\/a><\/div><\/div><div class=\"swiper-pagination\"><\/div><\/div><\/div>\n<\/div>\n<\/div>\n\n\n<section class=\"page page-home-s5 pt-media-9 pb-media-9\">\n<div class=\"container\">\n<div class=\"job wow fadeInLeft\">\n<h4 class=\"sub_title\">Talent Development<\/h4>\n<div class=\"des text32 mb-media-3\">We hope to <strong>invent radiopharmaceuticals for lives<\/strong> with you following the same <strong>heart and ideal<\/strong>. It&#8217;s a job, and moreover, it&#8217;s common endeavour.<\/div>\n<div class=\"go\"><a href=\"https:\/\/www.sinotau.com\/en\/join\/\">Join Us<i class=\"iconfont icon-right\"><\/i><\/a><\/div>\n<\/div>\n<\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"<p>Invent radiopharmaceuticals for lives Lays out oncology , neurology and cardiology Products Who We Are? A company ahead of the innovative radiopharmaceuticals in China. Since 2014, Sinotau started the R&amp;D of next-generation radiopharmaceuticals,which is an innovative pharmaceutical company specializing in the R&amp;D, production, clinical application and marketing of radiopharmaceuticals About Sinotau 9 Year+ Years of [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"inline_featured_image":false,"footnotes":""},"class_list":["post-3626","page","type-page","status-publish","hentry"],"meta_box":{"salary":[],"career":[]},"_links":{"self":[{"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/pages\/3626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/comments?post=3626"}],"version-history":[{"count":46,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/pages\/3626\/revisions"}],"predecessor-version":[{"id":4756,"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/pages\/3626\/revisions\/4756"}],"wp:attachment":[{"href":"https:\/\/www.sinotau.com\/en\/wp-json\/wp\/v2\/media?parent=3626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}